Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.42 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26754604 | 1.00 | HSD11B1 (0.64) | HSD11B1ALDH1A1ATMTP53TPSAB1 | |
| SCHEMBL26746721 | 0.86 | HSD11B1 (0.46) | HSD11B1TPSAB1TPSD1TPSG1KMT2A | |
| SCHEMBL26747551 | 0.86 | ALDH1A1 (0.46) | HSD11B1ALDH1A1ATMTP53TPSAB1 | |
| SCHEMBL26706267 | 0.86 | ALDH1A1 (0.46) | HSD11B1ALDH1A1ATMTP53TPSAB1 | |
| SCHEMBL26706122 | 0.85 | HSD11B1 (0.45) | HSD11B1ALDH1A1ATMTP53TPSAB1 | |
| SCHEMBL26746728 | 0.85 | HSD11B1 (0.45) | HSD11B1ALDH1A1ATMTP53TPSAB1 | |
| SCHEMBL29316808 | 0.85 | HSD11B1 (0.45) | HSD11B1ALDH1A1ATMTP53TPSAB1 | |
| SCHEMBL29330618 | 0.79 | HSD11B1 (0.39) | HSD11B1KMT2ASMN1; SMN2 | |
| SCHEMBL26746322 | 0.79 | HSD11B1 (0.39) | HSD11B1KMT2ASMN1; SMN2 | |
| SCHEMBL26746716 | 0.78 | TPSAB1 (0.44) | HSD11B1ALDH1A1ATMTP53TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | HSD11B1 2940/4885ALDH1A1 1138/4885ATM 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.